Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
XALience
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
- NCT07213674 ↗
- Recruiting
- Amgen
- Focused
We haven't built an HCP commentary report on XALience (xaluritamig, abiraterone acetate and 2 more in Metastatic Castration-resistant Prostate Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on XALience so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- Xaluritamig; Abiraterone acetate; Docetaxel; Cabazitaxel
- Arms
- Xaluritamig Plus Abiraterone · Experimental
- Investigator's Choice · Active comparator
- Enrollment
- 750 (estimated)
- Primary outcomes
- OS
- Sponsor
- Amgen
- Start
- Nov 28, 2025
- Primary completion
- Jan 7, 2030 (estimated)
- Results posted
- No
- Registry record
- NCT07213674 · updated Oct 20, 2026